The primary sclerosing cholangitis (PSC) market is characterized by inflammatory and fibrotic strictures of the bile ducts leading to cholestasis. PSC is a progressive disorder of unknown etiology. The signs and symptoms of PSC include jaundice, fatigue, pruritus, abdominal pain and fever. Currently, ursodeoxycholic acid is the only approved therapy for PSC but it only provides relief from symptoms, rather than slowing disease progression. There is no cure for PSC and patients usually require a liver transplant.
The global primary sclerosing cholangitis market is estimated to be valued at US$ 2.29 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the primary sclerosing cholangitis market are Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, HighTide Therapeutics Inc., and Tobira Therapeutics, Inc. Intercept Pharmaceuticals is a leading player in the market with its drug obeticholic acid currently under review by the FDA for approval.
The key factor driving the growth of the primary sclerosing cholangitis market is the increasing prevalence of inflammatory bowel disease (IBD), which is associated with higher risk of PSC. Approximately 10-15% of patients with IBD also develop PSC. In addition, growing awareness programs by patient advocacy groups and focus on early diagnosis are also supporting the market growth.
Advances in genomics and disease understanding are facilitating drug development for PSC. Several new molecules targeting specific disease pathways are under clinical trials. For instance, HighTide Therapeutics' HTD1801 drug targets pathways implicated in cholangiocyte loss and fibrosis. This offers hope of the first disease modifying therapy for PSC patients.
Market Trends
Increasing investment into clinical research for developing innovative drug therapies- Several pharmaceutical companies have increased their investment into research and clinical trials for evaluating new molecular entities and drug targets such as FXR agonists, ASBT inhibitors and immunomodulators for treatment of PSC.
Focus on combination therapies and novel drug delivery systems- Researchers are exploring efficacy of combination of existing drugs such as ursodeoxycholic acid with immunomodulators. Also, drug delivery systems such as nanoparticle formulations are being studied to enhance drug bioavailability and treatment outcomes.
Market Opportunities
Growing diagnosis rates especially in developing nations presents commercialization opportunities for drug developers. Also, development of non-invasive diagnostic tools will support early detection of disease.
Establishing collaborative networks between research institutes, pharma companies and patient advocacy groups can boost clinical trial participation and drug development process.
Impact of COVID-19 on Primary Sclerosing Cholangitis Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Primary Sclerosing Cholangitis Market Demand. The imposition of nationwide lockdowns led to the temporary closure of manufacturing units and disruptions in the supply chain, affecting the production and distribution of drugs used in the treatment of primary sclerosing cholangitis. Hospital visits and non-essential surgeries were deferred to focus medical resources on COVID patients. This led to delayed diagnosis and treatment for primary sclerosing cholangitis patients.
However, with the gradual lifting of lockdowns and development of COVID vaccination programs, the primary sclerosing cholangitis market is recovering. Manufacturers are resuming full-scale operations while implementing social distancing and safety measures. Telehealth and remote monitoring solutions are being utilized to continue care for patients without physical visits. Governments and private organizations are providing financial support to develop new treatment options and accelerate drug research. It is expected that the market will witness steady growth in the coming years backed by increased awareness, rapid diagnosis, and availability of advanced therapeutics.
Geographical Regions with Highest Market Value for Primary Sclerosing Cholangitis
North America holds the highest value share in the primary sclerosing cholangitis market owing to the large patient pool and rising disease prevalence in the United States. Availability of advanced healthcare infrastructure and reimbursement coverage for ursodeoxycholic acid therapy and liver transplantation has boosted drug uptake. North America is followed by Europe, especially Western European countries with well-developed healthcare systems and higher spending on specialty medicines.
Fastest Growing Region for Primary Sclerosing Cholangitis Market
Asia Pacific region is poised to witness the fastest growth in the primary sclerosing cholangitis market over the forecast period. This can be attributed to improving healthcare standards, increasing focus on rare disease diagnosis and management, growing per capita incomes, and expansion activities by leading market players. Governments are implementing various initiatives to boost awareness about conditions like primary sclerosing cholangitis and benefit more patients through subsidized treatment cost. The market will further gain traction with ongoing clinical trials evaluating novel therapeutic molecules.
Get More Insights On: Primary Sclerosing Cholangitis Market
